

ASTRAZENECA PLC  
Form 6-K  
December 04, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of (December 2018)

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1.  
Director/PDMR Shareholding

4 December 2018 15:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

AstraZeneca PLC (the Company) announces that, on 3 December 2018, Marc Dunoyer, a person discharging managerial responsibilities (PDMR) exercised an option to purchase 544 of the Company's ordinary shares of \$0.25 each (Ordinary Shares) at a price of £33.07 per Ordinary Share, under the AstraZeneca PLC 2012 Savings Related Share Option Scheme (Sharesave).

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name  
Marc Dunoyer

2 Reason for the notification

a) Position/status  
Chief Financial Officer

b) Initial notification /Amendment  
Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name  
AstraZeneca PLC

b) LEI  
PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|   |  |           |
|---|--|-----------|
| Description of the financial instrument, type of instrument | Ordinary Shares of US\$0.25 each in AstraZeneca PLC  |           |
| a) Identification code                                      | GB0009895292   |           |
| b) Nature of the transaction                                | Exercise of option to purchase shares under the AstraZeneca PLC 2012 Savings Related Share Option Scheme (Sharesave) |           |
| c) Price(s) and volume(s)                                   | Price(s)   | Volume(s) |
|   | £33.07   | 544       |
| Aggregated information                                      | Not applicable - single transaction  |           |
| d) - Aggregated volume                                      |  |           |
| - Price   |  |           |
| e) Date of the transaction                                  | 3 December 2018  |           |
| f) Place of the transaction                                 | Outside a trading venue  |           |

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

Media Relations

|                  |           |                  |
|------------------|-----------|------------------|
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding     | UK/Global | +44 203 749 5821 |
| Matt Kent        | UK/Global | +44 203 749 5906 |
| Gonzalo Viña     | UK/Global | +44 203 749 5916 |
| Jennifer Hursit  | UK/Global | +44 7384 799 726 |
| Jacob Lund       | Sweden    | +46 8 553 260 20 |
| Michele Meixell  | US        | +1 302 885 2677  |

|                     |                            |                  |
|---------------------|----------------------------|------------------|
| Investor Relations  |                            |                  |
| Thomas Kudsk Larsen |                            | +44 203 749 5712 |
| Henry Wheeler       | Oncology                   | +44 203 749 5797 |
| Christer Gruvris    | Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone          | Respiratory; Renal         | +44 203 749 5716 |
| Josie Afolabi       | Other                      | +44 203 749 5631 |
| Craig Marks         | Finance; Fixed Income      | +44 7881 615 764 |
| Jennifer Kretzmann  | Retail Investors           | +44 203 749 5824 |
| US toll-free        |                            | +1 866 381 7277  |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 04 December 2018

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary